462 related articles for article (PubMed ID: 11180504)
1. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Teismann P; Ferger B
Synapse; 2001 Feb; 39(2):167-74. PubMed ID: 11180504
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
4. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
5. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Ferger B; Teismann P; Earl CD; Kuschinsky K; Oertel WH
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):256-61. PubMed ID: 10543426
[TBL] [Abstract][Full Text] [Related]
6. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
7. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
[TBL] [Abstract][Full Text] [Related]
8. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Klivenyi P; Gardian G; Calingasan NY; Yang L; Beal MF
J Mol Neurosci; 2003; 21(3):191-8. PubMed ID: 14645986
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
Anderson DW; Neavin T; Smith JA; Schneider JS
Brain Res; 2001 Jun; 905(1-2):44-53. PubMed ID: 11423078
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra.
Feng ZH; Wang TG; Li DD; Fung P; Wilson BC; Liu B; Ali SF; Langenbach R; Hong JS
Neurosci Lett; 2002 Sep; 329(3):354-8. PubMed ID: 12183047
[TBL] [Abstract][Full Text] [Related]
12. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
13. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of riluzole in MPTP-treated mice.
Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
[TBL] [Abstract][Full Text] [Related]
15. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Morgan WW; Nelson JF
Brain Res; 2001 Dec; 921(1-2):115-21. PubMed ID: 11720717
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
19. 17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult.
Tripanichkul W; Sripanichkulchai K; Duce JA; Finkelstein DI
Brain Res; 2007 Aug; 1164():24-31. PubMed ID: 17640623
[TBL] [Abstract][Full Text] [Related]
20. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
